About Welgene
Welgene is a publicly listed company. Biotechnology products are provided by Taiwan-based Welgene. Welgene offers products and services including Next-Generation Sequencing and Proteomics Analysis. Its focus areas include Traditional Pharmaceuticals. Its legal entity is Welgene Biotech Co., Ltd.
Company details
Operations of Welgene are centered in Taiwan, where biotechnology solutions for life sciences are developed and distributed. Products including cell culture media, molecular biology reagents, and lab consumables are offered to research institutions and industries. Focus is placed on quality control and regulatory compliance in the biotech sector, supporting applications in pharmaceuticals and academic research across Asia. No specific founding year is documented in available records.
- Stage Public
- SectorsHealthcare
- Website welgene.com.tw
- Social Facebook
- Legal Name Welgene Biotech Co., Ltd.
- Annual Revenue$375.94 M16.55as on Dec 31, 2025
- Net Profit$1.33 M20.14as on Dec 31, 2025
- EBITDA$27.92 M-0.09as on Dec 31, 2025
Products & Services of Welgene
Welgene offers a comprehensive portfolio of products and services, including Next-Generation Sequencing and Proteomics Analysis.
Next-generation sequencing services are offered for genomic analysis and related applications
Proteomics analysis services are provided for protein studies in clinical and research contexts
IPO & Listings of Welgene
Welgene is a publicly listed company on the TPEX with ticker symbol 6661 in Taiwan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Jan 2021
- Listed onTT: 6661
- Listed entityWelgene Biotech Co., Ltd.
- Exchange sectorHealth technology
- ISINTW0006661002
- Share price17.00 TWD (+2.41% on the day) · 2026-10-14
- Market capitalisation386,850,539.00 TWD
- Price to earnings268.1
- EPS (diluted, trailing year)-0.07 TWD
- Volume (last session)8,000
Financials of Welgene
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 375.9M TWD | 1.3M TWD | 27.9M TWD |
| 2024 | 322.6M TWD | 1.1M TWD | 27.9M TWD |
| 2023 | 280.6M TWD | -2.6M TWD | 23.0M TWD |
| 2022 | 321.9M TWD | 9.6M TWD | 36.3M TWD |
| 2021 | 312.6M TWD | 13.7M TWD | 33.5M TWD |
Detailed financial statements for Welgene
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Welgene
The website of Welgene (welgene.com.tw) receives about 2K visits a month.
- Monthly visits2K
▲ 0.8% vs previous month
Websites whose visitors overlap most with Welgene. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
blossombio.com | blossombio.com | 100% | #2,010,078 | – | |
| dnanexus.com | 98% | 169.9K | #188,198 | View details | |
mlsb.kmu.edu.tw | mlsb.kmu.edu.tw | 96% | – | ||
ngs.ym.edu.tw | ngs.ym.edu.tw | 92% | – | ||
microarrays.ca | microarrays.ca | 90% | #12,064,388 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 15 similar websites and full traffic analytics for Welgene
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Welgene
Operations of Welgene are centered in Taiwan, where biotechnology solutions for life sciences are developed and distributed. Products including cell culture media, molecular biology reagents, and lab consumables are offered to research institutions and industries. Focus is placed on quality control and regulatory compliance in the biotech sector, supporting applications in pharmaceuticals and academic research across Asia. No specific founding year is documented in available records.
Welgene offers Next-Generation Sequencing and Proteomics Analysis.
Yes, Welgene is publicly traded on TPEX under the ticker symbol 6661.
Welgene operates through Welgene Biotech Co., Ltd.